Accelerate biotechnology

We won FD Gazellen Award 2017!

Yesterday, Batavia Biosciences has been awarded with an FD Gazellen Award 2017 by the leading Dutch financial newspaper, Financieel Dagblad as one of the fastest growing mid-sized companies of the Netherlands. It is the third time we have won a FD Gazellen Award and we hope that many more will follow.


Batavia Biosciences increases its presence in France and rest of Europe

The commercial team is strengthened with the arrival of Oréda Boussadia, PhD, MBA. She has extensive experience in the therapeutic proteins field from the research to the clinic. See looks very much forward to meet with you and introduce Batavia Biosciences’ latest capabilities, technologies and innovation. Oréda will be present at: • European Antibody Congress in…


Batavia Biosciences teams up with international gene therapy consortium under Horizon2020 program

An international consortium, headed by the group of Prof. Dr. Frank Staal (Department of Immunohematology and Blood Transfusion, Leiden University Medical Centre) has been awarded a €6 million grant from the European Union to develop a gene therapy procedure for newborns suffering from severe combined immunodeficiency syndrome (SCID). According to Prof. Dr. Frank Staal, the development…


Wouter van Catz is Best Biopharmaceutical CFO

We congratulate our Director Finance, Wouter van Catz with being awarded Best Biopharmaceutical CFO of the Benelux in the Global CFO Excellence Awards 2017. These awards have been established to recognize CFO’s whose efforts give rise to the success of the firm. According to the voters of respected industry partners and CFO Monthly‘s own rigorous in-house…


Collaboration between Batavia Biosciences and UGA Biopharma

Both companies have the ambition to provide services and technologies supporting the development of high quality and affordable biopharmaceuticals. Through the partnership, two enzyme expressing monoclonal cell lines are now delivered. They were developed and validated by Batavia Biosciences using STEP® technology, and were guided by UGA Biopharma´s in-depth knowledge and experience in the development…


Novel plasmid technology at PEGS Boston

Our Director Operations, Marco Cacciuttolo, presented interesting new case studies for our STEP® Technology at the PEGS summit in Boston . For various ‘difficult to express proteins’ Batavia Biosciences was able to significantly increase product yields in CHO cells. Missed the presentation and interested in receiving more information? Please visit our booth or contact us at info@bataviabiosciences.com.


How to improve Dutch life sciences landscape of translational research?

Batavia Biosciences hosted the Medical Delta Café: From ‘Bench to Bin’? Delegates representing Dutch industry, academia, technology transfer offices, government and funders came together to discuss the relatively high failure rate (and potential solutions) in the Dutch life sciences landscape of translational research. Read what we can learn from the successes of Harvard Medical School…


Univercells and consortium partners Batavia Biosciences and Natrix Separations Received $12 Million Grant by Bill & Melinda Gates Foundation to Radically Reduce Vaccine Costs for Developing Countries

Univercells and consortium partners Batavia Biosciences and Natrix Separations selected by Bill & Melinda Gates Foundation to Radically Reduce Vaccine Costs for Developing Countries   Brussels, Belgium, December 15, 2016 – Univercells announced today that it has been awarded a $12 million grant by the Bill & Melinda Gates Foundation for the development of a breakthrough vaccine manufacturing…


Reduce time to market, increase success rate with SCOUT®

Only 1 out of each 50 biopharmaceutical new product candidates makes it through the research phase into clinical trial testing and subsequently to the market. This high attrition rate is predominantly in the early development phases and is attributed to (I) undesired pharmacokinetics profile (39%), (II) lack of efficacy (30%), (III) in vivo toxicity in…